Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.
Ponatinib is a tyrosine kinase receptor inhibitor that is used in the therapy of refractory chronic myelogenous leukemia (CML) positive for the Philadelphia chromosome. Ponatinib is commonly associated with transient elevations in serum aminotransferase levels during treatment, but with only rare instances of clinically apparent acute liver injury.
Professional Ponatinib Api manufacturer is located in China, including Ponatinib Cas 943319-70-8,Ap24534 Ponatinib Cs-165,Iclusig Ponatinib Api, etc. Ponatinib Api,Ponatinib Cas 943319-70-8,Ap24534 Ponatinib Cs-165,Iclusig Ponatinib Api  Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com
 Â
Â
Â
 Â
Â
Â
Â
Â
Â
Â
Â
 Â
Â
Â
 Â
Â
Â
Â
Â
Â
Â
Â
Tire Valve Extensions, Valves Extension
Model NO.: Extensions
Model NO.: Extensions
Tire valve extensions
Tire valve extensions